Search clinical trials for: Biological/Vaccine: BNT162b2 10mcg

Total 258 results

GlaxoSmithKline

Completed

COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Argentina, Panama, Colombia
Jiangsu Province Centers for Disease Control and...

Completed

Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine .

Adverse Effect and Immunogenicity of Vaccine

China
GlaxoSmithKline

Completed

Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
GlaxoSmithKline

Completed

Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older

Influenza

Spain, United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Influenza

Korea, Republic of
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Measles | Rubella | Mumps | Measles-Mumps-Rubella Vaccine

Finland, Thailand, United States, Spain, Czechia, Puerto Rico, Malaysia
GlaxoSmithKline

Completed

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

Infections, Papillomavirus

Germany, Canada
GlaxoSmithKline

Completed

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

Tetanus | Diphtheria | Acellular Pertussis

United States
Centers for Disease Control and Prevention

Withdrawn

Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya

Tetanus | HIV | Malaria | Influenza, Human | Polio

Kenya
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Infections, Papillomavirus | Papillomavirus Vaccines

Thailand, Estonia, India, Brazil
GlaxoSmithKline

Completed

A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females

Infections, Papillomavirus

China
GlaxoSmithKline

Completed

Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years

Infections, Papillomavirus

Netherlands
The University of Queensland
Syneos Health; Coalition for Epidemic Preparedness Innovations

Completed

A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

Covid19 | SARS-CoV2

Australia
Lisata Therapeutics, Inc.

Terminated

Vaccine Therapy in Treating Patients With Kidney Cancer

Kidney Cancer

United States
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland
The Aurum Institute NPC
Coalition for Epidemic Preparedness Innovations

Recruiting

Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults. (AUR1-8-341)

COVID-19

South Africa
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

Malaria | Malaria Vaccines

Ghana
Talaris Therapeutics Inc.
Northwestern University

No longer available

Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)

Renal Failure

United States
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children

Influenza

Australia, Singapore
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | COVID-19 Infection

United States
Institut du Cancer de Montpellier - Val d'Aurelle

Recruiting

Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer (PANC-O-MICS)

Pancreas Cancer

France
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

Herpes Zoster | Herpes Zoster Vaccine

Canada, Spain, Korea, Republic of, United Kingdom, France, Czechia
Kanuni Sultan Suleyman Training and Research Hospital

Completed

Treatment of Angiotensin Peptide (1-7) for COVID-19

COVID-19

Turkey
GlaxoSmithKline

Completed

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

Infections, Papillomavirus

Germany, Taiwan, Thailand, Canada, Italy
GlaxoSmithKline

Completed

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Infections, Papillomavirus

Canada, Denmark, Hungary, Sweden
GlaxoSmithKline

Completed

Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants

Infections, Rotavirus

China
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Herpes Zoster

Germany, Canada, United States
GlaxoSmithKline

Completed

A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants

Infections, Streptococcal

Bangladesh
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children

Malaria

Kenya
GlaxoSmithKline

Completed

Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Influenza

Germany, United States, Belgium, Norway
GlaxoSmithKline

Completed

Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A

Influenza

Germany, Sweden, United Kingdom, Netherlands
GlaxoSmithKline

Completed

A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults

Respiratory Disorders

Belgium
University Hospital, Caen

Completed

Transverse Myelitis Related to SARS-CoV-2 Vaccines

Vaccine Adverse Reaction

France
Mebo Research, Inc.
Aurametrix

Active, not recruiting

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

COVID-19 Vaccines

United States, Georgia, Kenya, United Kingdom
Madhu Chhanda Choudhary
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy (NETI)

HIV Infections

United States
GlaxoSmithKline

Completed

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Infections, Papillomavirus

United States, Spain, Finland, Germany, Taiwan, Belgium, Philippines, Canada, Australia, United Kingdom, Thailand, Brazil, Italy, Mexico
National Cancer Institute (NCI)

Recruiting

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

Lynch Syndrome

United States, Puerto Rico
GlaxoSmithKline

Completed

Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines

Singapore
Universiteit Antwerpen
National Institute of Hygiene and Epidemiology, Vietnam

Completed

Pertussis (Tdap) Vaccination in Pregnancy

Pertussis | Pregnancy

Belgium, Vietnam
GlaxoSmithKline
Aeras

Completed

Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342

Tuberculosis

Belgium
GlaxoSmithKline

Completed

Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly

Influenza

Germany, United States, Belgium, Norway
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants

Malaria

Malawi
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region

Tuberculosis (TB) | Tuberculosis Vaccines

South Africa
GlaxoSmithKline

Completed

Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects

Infections, Cytomegalovirus

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

Infections, Papillomavirus

Japan
GlaxoSmithKline

Completed

Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control

Influenza

Canada
GlaxoSmithKline

Completed

Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy Infants

Infections, Rotavirus

China
GlaxoSmithKline

Withdrawn

Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults

Influenza

3

Subscribe